Upper Gastrointestinal Cancer Playlist

Learn how Canadian experts consider clinical trial data, weight risks vs. benefits, discuss treatment options, and approach challenging cases of uGI cancer.

1. What is the clinical relevance of endpoints such as DFS and MDFS when selecting adjuvant therapy in the absence of OS data?
    Answered by Dr. Stephanie Snow

2. What treatment regimens would you consider in the case of patient with GEJ adenocarcinoma for whom the PD-L1 CPS is unknown?
    Answered by Dr. Kim Ma

3. What treatment regimens would you consider in the case of a patient with metastatic esophageal adenocarcinoma?
    Answered by Dr. Howard Lim

4. What data do we have to support the long-term efficacy of I-O treatment options in the first-line metastatic setting?
    Answered by Dr. Stephanie Snow

5. What is the role of biomarkers in treatment selection for your patients with metastatic uGI cancers?
    Answered by Dr. Stephanie Snow

6. For your patients with metastatic uGI cancer on I-O plus chemotherapy, when do you consider stopping chemotherapy and how do you do it?
    Answered by Dr. Daniel Breadner and Dr. Kim Ma

7. How does your multidisciplinary team make the decision to treat with FLOT or CROSS in the adjuvant setting?
    Answered by Dr. Daniel Breadner

8. How do you approach discussing adjuvant treatment options with your eligible patients?
    Answered by Dr. Daniel Breadner and Dr. Howard Lim

9. What data supports the role of adjuvant I-O in uGI cancers?
    Answered by Dr. Howard Lim

10. How do you balance risks vs. benefits, including QoL, OS, and toxicities, when making adjuvant treatment decisions?
    Answered by Dr. Howard Lim

11. What treatmentregimens would you consider in the case of a young female patient withmetastatic gastric adenocarcinoma? 
    Answered by Dr. Kim Ma

CPS: combined positive score - CROSS: carboplatin, paclitaxel, and radiation - DFS: disease-free survival - FLOT: 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel - GEJ: gastroesophageal junction - I-O: immuno-oncology - MDFS: metastatic disease-free survival - OS: overall survival - PD-L1: programmed cell death ligand 1 - QoL: quality of life - uGI: upper gastrointestinal